ADMA Biologics

ADMA Biologics is a biopharmaceutical public company, based in New Jersey, USA. ADMA Biologics was founded in 2004.

The Company manufactures, develops and commercializes human plasma and plasma-derived, targeted therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised at risk for certain infections.therapeutics for immunity-compromised patients. ADMA Biologics consists of ADMA BioManufacturing and ADMA BioCenters (Plasma Collection Centers).

ADMA BioManufacturing is implemented the end-to-end control of supply chain from plasma collection through plasma fractionation, purification, fill-finish and testing.

ADMA BioCenters currently consists of a network of 9 plasma collection centers in various stages of approval and development.First center opened in 2011.

The company has three FDA-licensed approved products:

ASCENIV™ (Immune Globulin Intravenous - slra, Human), is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

ASCENIV™ is a novel IG and the only product in its class produced by blending normal plasma with hyperimmune plasma using ADMA’s patented methods.

BIVIGAM® (Immune Globulin Intravenous, Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

NABI-HB® (hepatitis B immune globulin, human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection. Nabi-HB has been used for over 20 years to protect against hepatitis B

infection among newly exposed individuals.

Pipeline: S. pneumoniae for treatment of pneumococcal pneumonia infections.

Its specialty is to develop and commercialize plasma-derived, human immune globulins for the treatment and prevention of certain infectious diseases.

NASDAQ ticker is ADMA.

Top Institutional Holders are: Perceptive Advisors Llс, Nuveen Asset Management,

Vanguard Group, Inc., Boothbay Fund Management, Blackrock Inc.